Responsive image

Common name

[hydrazino(methyl)amino]methane

IUPAC name

[hydrazino(methyl)amino]methane

SMILES

NNN(C)C

Common name

[hydrazino(methyl)amino]methane

IUPAC name

[hydrazino(methyl)amino]methane

SMILES

NNN(C)C

INCHI

InChI=1S/C2H9N3/c1-5(2)4-3/h4H,3H2,1-2H3

FORMULA

C2H9N3

Responsive image

Common name

[hydrazino(methyl)amino]methane

IUPAC name

[hydrazino(methyl)amino]methane





Molecular weight

75.113

clogP

-1.985

clogS

0.448

Frequency

0.0003





HBond Acceptor

1

HBond Donor

3

Total Polar
Surface Area

41.29

Number of Rings

0

Rotatable Bond

1

Drug ID Common name Structure CAS Compound class Therapeutic area
FDBD00711 Dacarbazine Responsive image Antineoplastic Agents; Immunosuppressive Agents; Antineoplastic Agents, Alkylating; Alkylating Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; CYP2E1 Inhibitors; CYP2E1 Inducers; CYP2E1 Inducers (strong); For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.
1 , 1
FRAGNAME PDBID SIMILIRITY XSCORE SMILE HAC
4bhi_ligand_2_2.mol2 4bhi 0.571429 -5.97 [N+](C)(C)(C)[NH+](C)C 7
4bhi_ligand_1_2.mol2 4bhi 0.571429 -5.83 [N+](C)(C)(C)[NH2+]C 6
2i5j_ligand_1_0.mol2 2i5j 0.5 -5.08 CNN 3
1bma_ligand_3_185.mol2 1bma 0.363636 -5.40 C[N+](C)(NC=O)C 7
3aid_ligand_3_155.mol2 3aid 0.363636 -5.35 C[N+](C)(C)NC=O 7
2cem_ligand_3_164.mol2 2cem 0.363636 -5.32 C[NH+](NC=O)C 6
2cen_ligand_3_164.mol2 2cen 0.363636 -5.31 C[NH+](NC=O)C 6
2wkz_ligand_3_215.mol2 2wkz 0.363636 -5.31 [NH+](NC=O)(C)C 6
2xye_ligand_3_483.mol2 2xye 0.363636 -5.31 C[NH+](C)NC=O 6
929 , 93